Event: IASLC TTLC 2024

0:02:41

Delivery of tumor treatment fields (TTFields) in NSCLC

0:02:07

Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumors

0:01:44

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterations

0:02:00

Testing for rare mutations in lung cancer in the US

0:02:56

Non-TKI-based treatment options for EGFR-mutant lung cancer

0:05:13

How can ctDNA assess MRD and profile tumor types in lung cancer?

0:03:44

Evaluating the use of ctDNA as a biomarker in lung cancer